News - Pfizer, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 44 results

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

Actavis settles Celebrex patent challenge with Pfizer

24-04-2014

Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsLegalPatentsPfizerUSA

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Pfizer to appeal Court decision on Celebrex reissue patent

Pfizer to appeal Court decision on Celebrex reissue patent

13-03-2014

US pharma behemoth Pfizer confirmed today that the US District Court for the Eastern District of Virginia…

Anti-Arthritics/RheumaticsCelebrexLegalNorth AmericaPatentsPfizerPharmaceuticalUSA

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk

12-02-2014

The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Disappointment for Pfizer on negative CHMP view for Xeljanz

26-07-2013

There was disappointment for US pharma behemoth Pfizer (NNYSE: PFE), when the European Medicines Agency's…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationXeljanz

Pfizer gets Swiss nod for Xeljanz for rheumatoid arthritis

16-07-2013

US drug giant Pfizer (NYSE: PFE) said its rheumatoid arthritis (RA) therapy Xeljanz (tofacitinib) has…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationTakeda NycomedXeljanz

Bioventus in-licenses exclusive rights to Pfizer's BMP portfolio

02-07-2013

USA-based orthopedic healing specialist Bioventus, a spin out from the UK's Smith & Nephew to an Essex…

Anti-Arthritics/RheumaticsBioventusGlobalhyaluronic acidLicensingPfizerPharmaceutical

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors

17-06-2013

Bazedoxifene, a drug approved in some countries to treat osteoporosis, has now been shown to stop the…

Anti-Arthritics/RheumaticsbazedoxifeneOncologyPfizerPharmaceuticalResearch

Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?

10-06-2013

Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

EMA committee gives thumbs down for Pfizer's Xeljanz for RA

26-04-2013

Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationXeljanz

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015

06-03-2013

Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

1 to 25 of 44 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top